文章基本信息

标题：Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function
本地全文：下载
作者：Hamutal Meiri ; George Osol ; Irene Cetin 等
期刊名称：Computational and Structural Biotechnology Journal
印刷版ISSN：2001-0370
出版年度：2017
卷号：15
页码：433-446
DOI：10.1016/j.csbj.2017.09.002
语种：
出版社：Computational and Structural Biotechnology Journal
摘要：Hypertensive disorders affect about one third of all people aged 20 and above, and are treated with anti-hypertensive drugs. Preeclampsia (PE) is one form of such disorders that only develops during pregnancy. It affects ten million pregnant women globally and additionally causes fetal loss and major newborn disabilities. The syndrome's origin is multifactorial, and anti-hypertensive drugs are ineffective in treating it. Biomarkers are helpful for predict its development. Generic drugs, such as low dose aspirin, were proven effective in preventing preterm PE. However, it does not cure the majority of cases and many studies are underway for fighting PE with extended use of additional generic drugs, or through new drug development programs.
关键词：Preeclampsia ; Galectins ; LGALS13 ; Polymorphism ; Placenta ; Gene expression ; Promoter regulation ; Immune tolerance ; Endothelial layer ; Signaling pathways